My watch list  

MHRA Issues GMP Certification to AMRI UK Facility

19-01-2012: AMRI announced that the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government has issued a Good Manufacturing Practice (GMP) certificate for AMRI's manufacturing facility in Holywell, Wales, UK, following an inspection in October 2011. The MHRA inspection follows a U.S. Food and Drug Administration audit of the facility in June 2011, in which no formal observations were issued. The successful completion of the US FDA and UK MHRA inspections means that AMRI's Holywell facility can now produce registered intermediates and active ingredients for use in humans and expands the range of projects that AMRI can now conduct at this facility.

AMRI Vice President, Pharmaceutical Development and Manufacturing Steven R. Hagen, Ph.D. said, "This certification completes an excellent year of regulatory cGMP audits for the Holywell facility and places it in a prime position to attract new business. The certification also closes a highly successful year of numerous audits across our global facilities that align us with best industry practices."

In 2011, AMRI's Rensselaer facility, which provides large-scale cGMP manufacturing, was inspected by FDA, in which no formal observations were issued. In addition, the Company received an approval in February 2011 from the Italian Medicines Agency (AIFA) for its Burlington, Mass. facility to manufacture a commercial drug product for a customer in the European Union.

Facts, background information, dossiers
More about Albany Molecular Research
  • News

    AMRI Completes Acquisition of Oso Biopharmaceuticals Manufacturing

    AMRI announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug product development and manu ... more

    AMRI to Acquire Oso Biopharmaceuticals Manufacturing

    AMRI announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC ("OsoBio") for $110 million in cash. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile l ... more

    AMRI Announces Executive Leadership Changes

    Albany Molecular Research, Inc.  announced that Thomas E. D'Ambra, Ph.D. will retire as President and Chief Executive Officer of the Company, effective December 31, 2013. Dr. D'Ambra will be named the Company's non-executive Chairman of the Board of Directors on the same date. Dr. D'Ambra w ... more

More about Medicines and Healthcare Products Regulatory Agency
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE